Table 3.
Significantly enriched pathways for differentially expressed genes in intramuscular adipocytes.
| Pathway | Enriched genes | P–value |
|---|---|---|
| Calcium signaling pathway | ADCY2,ADRA1D, ATP2B2,CACNA1H, CAMK1D, CAMK2A, CAMK4,CASQ2,CD38,CXCR4,HTR2B, HTR4,ip3ka, ITPR3,NCX1,PLCD4,TBXA2R, TNNC1,TNNC2 | 0.000 |
| Adrenergic signaling in cardiomyocytes | ACTC1,ADCY2,ADRA1D, ATP1B1,ATP2B2,BCL2,CAMK2A, CREB5,Myl2,MYL3,MYL4,NCX1,TNNC1,TNNT2 | 0.000 |
| Focal adhesion | ACTB, BCL2,CAV3,CHAD, fn1,IGF1,ITGA1,ITGA9,LAMA5,Myl2,MYL9,PDGFB, PGF, PPP1R12B, SHC4,THBS1, VTN | 0.000 |
| Cardiac muscle contraction | ACTC1,ATP1B1,CASQ2,Myl2,MYL3,MYL4,NCX1,TNNC1,TNNT2, UQCR11 | 0.000 |
| Phosphatidylinositol signaling system | DGKB, DGKG, DGKQ, INPP5J, ip3ka, IP6K3,ITPK1,ITPR3,MTMR1,PIK3C2A, PLCD4 | 0.000 |
| Neuroactive ligand-receptor interaction | ADM, ADRA1D, CHRM4,CHRNA1,CHRND, CHRNG, CNR1,CRHR2,EDN1,EDN2,EP4,GIPR, GRID1,GRM3,HTR2B, HTR4,PENK, S1PR3,SS2R, TBXA2R, VPAC2 | 0.001 |
| Regulation of actin cytoskeleton | ACTB, APC2,ARHGEF4,CHRM4,CXCR4,FGF7,Fgf9,fn1,IQGAP2,ITGA1,ITGA9,Myl2,MYL9,PDGFB, PPP1R12B | 0.001 |
| ECM-receptor interaction | CD36,CHAD, fn1,ITGA1,ITGA9,LAMA5,NPNT, THBS1,VTN | 0.006 |
| AGE-RAGE signaling pathway in diabetic complications | BCL2,CDKN1B, EDN1,F3,fn1,IL6,NOX1,PLCD4,SELE | 0.007 |
| Cell adhesion molecules (CAMs) | CADM3,CDH3,CDH4,CLDN1,ITGA9,NFASC, NRCAM, SELE | 0.010 |
| PPAR signaling pathway | ACOX2,ADIPOQ, APOA1,CD36,FABP4,FABP5,LPL | 0.010 |